XOMA Corporation has licensed the global development and commercialization rights to its anti-transforming growth factor-beta (TGFb) antibody program to Novartis. XOMA will receive $37 million upfront and is eligible to receive up to $480 million if all development, regulatory, and commercial milestones are met. In addition, XOMA is eligible to receive royalties on product sales that range from the mid-single digits to the low double digits. “XOMA and Novartis have worked closely togeth...